Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry. Ms. Oliger currently serves on multiple public company boards, including Karyopharm Therapeutics, Replimune Group, and LAVA Therapeutics. She previously served on the boards of Sierra Oncology until its acquisition by GSK in 2022, Reata Pharmaceuticals until its acquisition by Biogen in 2023, and RayzeBio until its acquisition by Bristol Myers Squibb in 2024. In her most recent operational role, Ms. Oliger served as Genentech’s Senior Vice President, Oncology Business Unit Head from 2017 to 2020. During her 20-year tenure at Genentech, she held senior commercial leadership roles across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology, and immunology. In addition, while at Genentech Ms. Oliger held senior R&D roles, including leading the Roche global portfolio management function. Ms. Oliger holds a Bachelor of Arts in Economics from the University of California at Santa Barbara.